|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||14.29 - 14.60|
|52 Week Range||7.16 - 18.84|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jan 27, 2010|
|1y Target Est||18.00|
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcoming investor events – the Jefferies Virtual London Healthcare Conference and the Canaccord Genuity Virtual MedTech & Diagnostics Forum. Ms. Zaderej will present at the Jefferies London Healthcare Conference on Wednesday, November 18, 2020 at 3:15 p.m. (10:15 a.m. ET).She will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 10:00 a.m. ET.Both presentations will be webcast live and accessible through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard® Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.Contact: Axogen, Inc. Peter J. Mariani, chief financial officer firstname.lastname@example.org InvestorRelations@axogeninc.com
Greetings, and welcome to the AxoGen Third quarter earnings call [Operator Instructions] As a reminder, this conference is being recorded. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President. Karen will begin today's call with an overview of our third quarter performance and an update on the ongoing recovery in our markets.